3-D Life Hydrogel Used in Novel Microfluidic Platform to Investigate CAR-T Cell Therapy for Solid Tumors
Cellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read moreCellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read moreimusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read moreBristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read morePreclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read moreThe U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read moreIovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreIn a significant development for the fight against advanced small cell lung cancer (SCLC), the U.S. Food and Drug Administration
Read more